Hemophilia in the emergency department

Hemofilia en urgencias

Published 2025-02-25

Open | Download
PDF (Spanish) FLIP HTML (Spanish) text/xml XML (Spanish) EPUB (Spanish) audio/mpeg MP3 (Spanish)
Issue
Vol. 34 No. 1 (2025): Enero-Abril
Section
Review Articles
How to Cite
Ceron Luna, S., Roldan, M. D., & Martínez, L. M. (2025). Hemophilia in the emergency department. Journal of Medicine and Surgery Repertoire, 34(1), 7-12. https://doi.org/10.31260/RepertMedCir.01217372.1433
DOI

https://doi.org/10.31260/RepertMedCir.01217372.1433
Dimensions
PlumX
Citations
Crossref
Citations in Crossref
Scopus
Citations in Scopus
Google Scholar
Europe PMC
Citations in Europe PMC
license

   

Sebastian Ceron Luna
Pontifical Bolivarian University image/svg+xml
Roles:  
https://orcid.org/0000-0003-1449-9618

Mabel Dahiana Roldan
Pontifical Bolivarian University image/svg+xml
Roles:  
Perfil Google Scholar
Lina María Martínez
Pontifical Bolivarian University image/svg+xml
Roles:  
Perfil Google Scholar
Show authors biography

Sebastian Ceron Luna,

Estudiante de Medicina. Universidad Pontificia Bolivariana. Escuela Ciencias de la Salud,  Facultad de Medicina. Medellín, Colombia.

Mabel Dahiana Roldan,

Médica. Universidad Pontificia Bolivariana. Escuela Ciencias de la Salud, Facultad de Medicina. Medellín, Colombia. 

Lina María Martínez,

Asesora Metodológica, Bacterióloga, Esp. en Hematología, Mag. en Educación. Universidad Pontificia Bolivariana. Escuela de Ciencias de la Salud. Facultad de Medicina. Medellín, Colombia

Introduction: hemophilia is an inherited bleeding disorder in which the blood does not clot properly due to low levels of clotting factors VIII or IX, which can cause spontaneous bleeding. The severity of hemophilia is determined by the amount of factor in the blood. Objective: to identify the main sites of spontaneous bleeding and its complications, which is fundamental for care, prevention, and prognosis in these patients. Methods: a literature search performed in the Pubmed, Access Medina, ClinicalKey and Science Direct databases, between August 23, 2021, and January 2023. Discussion: we describe the complications and main characteristics of hemophilia affected individuals, the clinical manifestations related to hemorrhagic events, and that severity correlates with the blood level of clotting factors, as reported in the literature. Conclusions: both hemophilia A and B are associated with spontaneous bleeding or bleeding following injuries or surgery. Clinical presentations vary depending on the involved systems. Adequate factor replacement therapy helps prevent bleeding episodes and the development of complications. 

Article visits 498 | PDF visits 389

Downloads

Download data is not yet available.
  1. Müller J, Miesbach W, Prüller F, Siegemund T, Scholz U, Sachs UJ; Standing Commission Labor (STAEKOLA) of the Society of Thrombosis and Haemostasis Research (GTH). An Update on Laboratory Diagnostics in Haemophilia A and B. Hamostaseologie. 2022;42(4):248-260. http://dx.doi.org/10.1055/a-1665-6232 DOI: https://doi.org/10.1055/a-1665-6232
  2. Benson G, Auerswald G, Dolan G, Duffy A, Hermans C, Ljung R, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus. 2018;16(6):535-44. http://dx.doi.org/10.2450/2017.0150-17
  3. Constantinescu C, Jitaru C, Pasca S, Dima D, Dirzu N, Coriu D, Zdziarska J, Ghiaur G, Mahlangu J, Tomuleasa C. Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. Blood Rev. 2022;53:100907. http://dx.doi.org/10.1016/j.blre.2021.100907 DOI: https://doi.org/10.1016/j.blre.2021.100907
  4. Hotea I, Brinza M, Blag C, Zimta AA, Dirzu N, Burzo C, et al. Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology. Ann Transl Med. 2021;9(13):1091. http://dx.doi.org/10.21037/atm-21-747 DOI: https://doi.org/10.21037/atm-21-747
  5. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545-53. doi: 10.3324/haematol.2019.232132. DOI: https://doi.org/10.3324/haematol.2019.232132
  6. van Galen KPM, d'Oiron R, James P, Abdul-Kadir R, Kouides PA, Kulkarni R, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021;19(8):1883-87. http://dx.doi.org/10.1111/jth.15397 DOI: https://doi.org/10.1111/jth.15397
  7. Kloosterman F, Zwagemaker AF, Abdi A, Gouw S, Castaman G, Fijnvandraat K. Hemophilia management: Huge impact of a tiny difference. Res Pract Thromb Haemost. 2020;4(3):377-385. http://dx.doi.org/10.1002/rth2.12314 DOI: https://doi.org/10.1002/rth2.12314
  8. European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation. Factor VIII (F8) Variant Database [Internet]. Structural Immunology Group, University College London; 2013 [citado 16 enero de 2022]. Disponible en: www.factorviii-db.org
  9. European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation. Factor IX (F9) Variant Database [Internet]. EAHAD; 2022 [citado 16 enero de 2022]. Disponible: https://f9-db.eahad.org/
  10. Centers for Disease Control and Prevention. (CDC) Hemophilia A Mutation Project (CHAMP) [Internet]. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention; 2023. Disponible: http://www.cdc.gov/ncbddd/hemophilia/champs.html
  11. Centers for Disease Control and Prevention (CDC) Hemophilia B Mutation Project (CHBMP) [Internet]. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention; 2023. Disponible: http://www.cdc.gov/ncbddd/hemophilia/champs.html
  12. Konkle BA, Johnsen JM, Wheeler M, Watson C, Skinner M, Pierce GF; My Life Our Future programme. Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. Haemophilia. 2018;24 Suppl 6(Suppl 6):87-94. http://dx.doi.org/10.1111/hae.13506 DOI: https://doi.org/10.1111/hae.13506
  13. Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171(8):540-46. http://dx.doi.org/10.7326/M19-1208. DOI: https://doi.org/10.7326/M19-1208
  14. Croteau SE. Hemophilia A/B. Hematol Oncol Clin North Am. 2022;36(4):797-812. http://dx.doi.org/10.1016/j.hoc.2022.03.009 DOI: https://doi.org/10.1016/j.hoc.2022.03.009
  15. Sidonio RF Jr, Malec L. Hemophilia B (Factor IX Deficiency). Hematol Oncol Clin North Am. 2021;35(6):1143-1155. http://dx.doi.org/10.1016/j.hoc.2021.07.008 DOI: https://doi.org/10.1016/j.hoc.2021.07.008
  16. Forrest BP, de Klerk R, Baghaie H, Perry CF. Diagnosis of previously unidentified haemophilia A in a patient following routine endoscopic sinus surgery, Otolaryngology Case Reports. 2021;19: 100278. http://dx.doi.org/10.1016/j.xocr.2021.100278 DOI: https://doi.org/10.1016/j.xocr.2021.100278
  17. Chen YC, Chang CY, Cheng SN, Pan RY, Shih YL, Li TY, Wang SH. Evolution of congenital haemophilia care in Taiwan. J Formos Med Assoc. 2021;3:S0929-6646(21)00348-X. http://dx.doi.org/10.1016/j.jfma.2021.07.017 DOI: https://doi.org/10.1016/j.jfma.2021.07.017
  18. Miller CH, Bean CJ. Genetic causes of haemophilia in women and girls. Haemophilia. 2021;27(2):e164-e179. http://dx.doi.org/10.1111/hae.14186 DOI: https://doi.org/10.1111/hae.14186
  19. Sidonio RF Jr, Malec L. Hemophilia B (Factor IX Deficiency). Hematol Oncol Clin North Am. 2021;35(6):1143-1155. http://dx.doi.org/10.1016/j.hoc.2021.07.008 DOI: https://doi.org/10.1016/j.hoc.2021.07.008
  20. Seaman CD, Xavier F, Ragni MV. Hemophilia A (Factor VIII Deficiency). Hematol Oncol Clin North Am. 2021;35(6):1117-1129. http://dx.doi.org/10.1016/j.hoc.2021.07.006 DOI: https://doi.org/10.1016/j.hoc.2021.07.006
  21. Spadarella G, Di Minno A, Brunetti-Pierri N, Mahlangu J, Di Minno G. The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Rev. 2021;46:100737. http://dx.doi.org/10.1016/j.blre.2020.100737 DOI: https://doi.org/10.1016/j.blre.2020.100737
  22. Hodroj MH, El Hasbani G, Al-Shamsi HO, Samaha H, Musallam KM, Taher AT. Clinical burden of hemophilia in older adults: Beyond bleeding risk. Blood Rev. 2022;53:100912. http://dx.doi.org/10.1016/j.blre.2021.100912 DOI: https://doi.org/10.1016/j.blre.2021.100912
  23. Stephanos K, Dubbs SB. Pediatric Hematologic and Oncologic Emergencies. Emerg Med Clin North Am. 2021;39(3):555-571. http://dx.doi.org/10.1016/j.emc.2021.04.007 DOI: https://doi.org/10.1016/j.emc.2021.04.007
  24. Pasca S, Linari S, Tagliaferri A, Santoro C, Zanon E; EMO.REC study group. Very high risk of intracranial hemorrhage and severe outcomes in adult patients with mild hemophilia: Sub-analysis of the EMO.REC Registry. Thromb Res. 2023;221:35-36. http://dx.doi.org/10.1016/j.thromres.2022.11.015 DOI: https://doi.org/10.1016/j.thromres.2022.11.015
  25. Roderick PJ, Robinson AC, Life-threatening oro- pharyngeal bleeding in a haemophiliac with factor VIII inhibitors. Clin Lab Haemat, 1988;10(2):217-19. http://dx.doi.org/10.1111/j.1365-2257.1988.tb01174.x. DOI: https://doi.org/10.1111/j.1365-2257.1988.tb01174.x
  26. Hoots KW. Manejo de emergencia de la hemofilia. In: Textbook of Hemophilia, 3a ed, Lee CA, Berntorp EE, Hoots WK (Eds), John Wiley & Sons, Ltd; 2014. p1-11
  27. Shapiro AD, Hardesty BM, Peyvandi F, Iorio A. Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review. Res Pract Thromb Haemost. 20229;7(1):100007. http://dx.doi.org/10.1016/j.rpth.2022.100007 DOI: https://doi.org/10.1016/j.rpth.2022.100007
  28. Alblaihed L, Dubbs SB, Koyfman A, Long B. High risk and low prevalence diseases: Hemophilia emergencies. Am J Emerg Med. 2022;56:21-27. http://dx.doi.org/10.1016/j.ajem.2022.02.045 DOI: https://doi.org/10.1016/j.ajem.2022.02.045
  29. Mendoza O, Loayza N, Trujillo M, Herrera C, Yanac R, Ormeño W, et al. Guía de práctica clínica para el diagnóstico y tratamiento de hemofilia en el Seguro Social de Salud del Perú (EsSalud). An Fac med. 2018;79(1):83-93. http://dx.doi.org/10.15381/anales.v79i1.14598 DOI: https://doi.org/10.15381/anales.v79i1.14598
  30. Martínez-Sánchez L, Álvarez-Hernández L, Ruiz-Mejía C, Jaramillo-Jaramillo L, Builes-Restrepo L, Villegas-Álzate J. Hemofilia: abordaje diagnóstico y terapéutico. Revisión bibliográfica. Revista Facultad Nacional De Salud Pública. 2018;36(2):85-93. http://dx.doi.org/10.17533/udea.rfnsp.v36n2a11 DOI: https://doi.org/10.17533/udea.rfnsp.v36n2a11
  31. Di Minno G, Castaman G, De Cristofaro R, Brunetti-Pierri N, Pastore L, Castaldo G, Trama U, Di Minno M. Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. Blood Rev. 2023;58:101011. http://dx.doi.org/10.1016/j.blre.2022.101011 DOI: https://doi.org/10.1016/j.blre.2022.101011
  32. De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT, Martin-Salces M, Rivas-Pollmar I, Jimenez-Yuste V. Arthropathy in people with mild haemophilia: Exploring risk factors. Thromb Res. 2022;211:19-26. http://dx.doi.org/10.1016/j.thromres.2022.01.010 DOI: https://doi.org/10.1016/j.thromres.2022.01.010
  33. Hermans C, Noone D, Benson G, Dolan G, et al. Hemophilia treatment in 2021: Choosing the"optimal" treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Rev. 2022 Mar;52:100890. http://dx.doi.org/10.1016/j.blre.2021.100890 DOI: https://doi.org/10.1016/j.blre.2021.100890
  34. Aquino LM, Ranche FK. Hemophilia presenting as recurrent ocular hemorrhage. GMS Ophthalmol Cases. 2020;18;10:Doc15. http://dx.doi.org/ 10.3205/oc000142
  35. Aquino LM, Rancher FK. Hemophilia presenting as recurrent ocular hemorrhage. GMS Ophthalmol Cases. 2020;10(15):1-5 http://dx.doi.org/10.3205/oc000142
  36. Mehta P, Reddivari AKR. Hemophilia. 2022;30. In: StatPearls [Internet]. reasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551607/
  37. Ray A, Colville JG, Hartley R, Rowbotham E. The musculoskeletal manifestations of haemophilia: a review of the imaging findings. Clin Radiol. 2022;77(10):730-737. http://dx.doi.org/10.1016/j.crad.2022.06.022 DOI: https://doi.org/10.1016/j.crad.2022.06.022
  38. Batsuli G, Kouides P. Rare Coagulation Factor Deficiencies (Factors VII, X, V, and II). Hematol Oncol Clin North Am. 2021;35(6):1181-1196. http://dx.doi.org/10.1016/j.hoc.2021.07.010 DOI: https://doi.org/10.1016/j.hoc.2021.07.010
  39. Santo AH. Causes of death and mortality trends related to hemophilia in Brazil, 1999 to 2016. Hematol Transfus Cell Ther. 2021;43(2):171-178. http://dx.doi.org/10.1016/j.htct.2020.02.003 DOI: https://doi.org/10.1016/j.htct.2020.02.003
  40. Cho S, Perry AM, Cheng AM, Wang C, Rico JF. Advances in Hemophilia A Management. Adv Pediatr. 2022;69(1):133-147. http://dx.doi.org/10.1016/j.yapd.2022.03.009 DOI: https://doi.org/10.1016/j.yapd.2022.03.009
  41. W Keith Hoots A, Shapiro D, Leung L, Tirnauer J. Treatment of bleeding and perioperative management in hemophilia A and B. [Internet]. UpToDate. 2021 [citado 16 enero de 2022]. Disponible en: https://www-uptodate-com.consultaremota.upb.edu.co/contents/treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b?search=tratamiento%20de%20la%20hemofilia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H2996978111
  42. Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia 2018;24(1):24-32. http://dx.doi.org/10.1111/hae.13331 DOI: https://doi.org/10.1111/hae.13331
Tutorials

Autors:

How send article?

Evaluator pair

Information

Keywords

Indexed in


Google Scholar profile

QR code

Most read in the last 30 days

Sistema OJS 3.4.0.5 - Metabiblioteca |